Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 29, Issue 2, Pages 57-61Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2007.11.004
Keywords
-
Categories
Funding
- NCI NIH HHS [CA96504, R01 CA096504, CA101830, R01 CA096504-07, R01 CA101830-04, R01 CA101830] Funding Source: Medline
- NIGMS NIH HHS [T32 GM008334] Funding Source: Medline
Ask authors/readers for more resources
The development of antibody therapies for cancer is increasing rapidly, primarily owing to their specificity. Antibody distribution in tumors is often extremely uneven, however, leading to some malignant cells being exposed to saturating concentrations of antibody, whereas others are completely untargeted. This is detrimental because large regions of cells escape therapy, whereas other regions might be exposed to suboptimal concentrations that promote a selection of resistant mutants. The distribution of antibody depends on a variety of factors, including dose, affinity, antigens per cell and molecular size. Because these parameters are often known or easily estimated, a quick calculation based on simple modeling considerations can predict the uniformity of targeting within a tumor. Such analyses should enable experimental researchers to identify in a straightforward way the limitations in achieving evenly distributed antibody, and design and test improved antibody therapeutics more rationally.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available